Sanaria® PfSPZ-LARC2 Vaccine the focus of a meeting at Germany’s biologics regulatory agency, the Paul-Ehrlich-Instit.

DZIF Workshop on Malaria Vaccine Development

On the 29th of May 2024 the DZIF Product Development Unit (PDU) and the Translational Thematic Unit
(TTU) on Malaria and Neglected Tropical Diseases met for a workshop on malaria vaccine development
at the Paul-Ehrlich-Institut, Germany. The aim was to discuss the development strategy of the different
DZIF malaria vaccine projects with a view to clinical application, target populations and market access.
Dr. Stephen Hoffman, Chief Executive and Scientific Officer and Chairman of Sanaria Inc., participated
in the meeting to complement and support the discussion as Sanaria Inc. is manufacturing Plasmodium
falciparum sporozoites and is a long-standing collaborator of DZIF´s TTU Malaria and Neglected
Tropical Diseases. This was the first time that DZIF principal investigators, members of the DZIF PDU,
regulatory experts of the Paul-Ehrlich-Institut and Sanaria Inc. came together to discuss and advance
the development of the DZIF malaria vaccine projects with attainable positive impact on people living
in Europe and Africa.